Literature DB >> 11953423

Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.

Jijie Gu1, Hidehiko Kawai, Linghu Nie, Hiroyuki Kitao, Dmitri Wiederschain, Aart G Jochemsen, John Parant, Guillermina Lozano, Zhi-Min Yuan.   

Abstract

MDMX, an MDM2-related protein, has emerged as yet another essential negative regulator of p53 tumor suppressor, since loss of MDMX expression results in p53-dependent embryonic lethality in mice. However, it remains unknown why neither homologue can compensate for the loss of the other. In addition, results of biochemical studies have suggested that MDMX inhibits MDM2-mediated p53 degradation, thus contradicting its role as defined in gene knockout experiments. Using cells deficient in either MDM2 or MDMX, we demonstrated that these two p53 inhibitors are in fact functionally dependent on each other. In the absence of MDMX, MDM2 is largely ineffective in down-regulating p53 because of its extremely short half-life. MDMX renders MDM2 protein sufficiently stable to function at its full potential for p53 degradation. On the other hand, MDMX, which is a cytoplasmic protein, depends on MDM2 to redistribute into the nucleus and be able to inactivate p53. We also showed that MDMX, when exceedingly overexpressed, inhibits MDM2-mediated p53 degradation by competing with MDM2 for p53 binding. Our findings therefore provide a molecular basis for the nonoverlapping activities of these two p53 inhibitors previously revealed in genetic studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953423     DOI: 10.1074/jbc.C200150200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  120 in total

1.  DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.

Authors:  Changgong Li; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Critical role for a central part of Mdm2 in the ubiquitylation of p53.

Authors:  Erik Meulmeester; Ruth Frenk; Robert Stad; Petra de Graaf; Jean-Christophe Marine; Karen H Vousden; Aart G Jochemsen
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

3.  Critical contribution of the MDM2 acidic domain to p53 ubiquitination.

Authors:  Hidehiko Kawai; Dmitri Wiederschain; Zhi-Min Yuan
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

4.  Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.

Authors:  Jayne M Stommel; Geoffrey M Wahl
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

5.  Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers.

Authors:  Pavlina Dolezelova; Katerina Cetkovska; Karen H Vousden; Stjepan Uldrijan
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

6.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

7.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

8.  MDMX regulation of p53 response to ribosomal stress.

Authors:  Daniele M Gilkes; Lihong Chen; Jiandong Chen
Journal:  EMBO J       Date:  2006-11-16       Impact factor: 11.598

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

10.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.